Cell-free RNA Liquid Biopsy to Monitor Hematopoietic Stem Cell Transplantation.

Autor:	Loy C; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.; Department of Molecular Biology and Genetics, Cornell University; Ithaca, 14853, USA., Cheng MP; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, 02215, USA.; Division of Infectious Disease, Brigham and Women's Hospital; Boston, 02215, USA., Gonzalez-Bocco IH; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, 02215, USA.; Division of Infectious Disease, Brigham and Women's Hospital; Boston, 02215, USA., Lenz J; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA., Belcher E; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA., Bliss A; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA., Eweis-LaBolle D; Department of Molecular Biology and Genetics, Cornell University; Ithaca, 14853, USA., Chu T; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, 02215, USA.; Department of Medicine, Harvard Medical School, Boston, 02115, USA., De Vlaminck I; Meinig School of Biomedical Engineering, Cornell University; Ithaca, 14850, USA.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2024 May 16. Date of Electronic Publication: 2024 May 16.
DOI:	10.1101/2024.05.15.24307448
Abstrakt:	Hematopoietic Stem Cell Transplantation (HSCT) is one of the oldest and most successful immunotherapies. Yet, despite long-standing success in the use of HSCT for the treatment of blood cancers and severe immune disorders, monitoring post-transplant complications remains a challenge due to a lack of informative diagnostic tests. Here, we investigate the utility of cell-free RNA (cfRNA) in plasma as a liquid biopsy to monitor allogeneic HSCT recipients during and after treatment. We assayed longitudinal samples from 92 HSCT recipients by cfRNA sequencing and show that cfRNA provides insight into treatment and recovery trajectories, immune dynamics in response to transplantation, infection, and solid-tissue injury associated with Graft-Versus-Host Disease. Collectively, our results provide support for the use of plasma cfRNA profiling to monitor complications of HSCT. Competing Interests: C.J.L and I.D.V are inventors on submitted patents pertaining to cell-free nucleic acids (US patent applications 63/237,367 and 63/429,733). I.D.V. is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. I.D.V. is listed as an inventor on submitted patents pertaining to cell-free nucleic acids (US patent applications 63/237,367, 63/056,249, 63/015,095, 16/500,929, 41614P-10551-01-US) and receives consulting fees from Eurofins Viracor. JR receives research funding from Kite/Gilead, Novartis and Oncternal Therapeutics and serves on advisory boards for Garuda Therapeutics, LifeVault Bio, Smart Immune and TriArm Therapeutics. MPC reports research support from the Canadian Institutes of Health Research and is supported by the Fonds de Recherche du Québec - Santé; research contracts from Cidara Therapeutics, Scynexis, and Amplyx Pharmaceuticals; honoraria from AstraZeneca, Takeda, Merck, and Pfizer; 3 pending patents (Methods for detecting tissue damage, graft-versus-host disease, and infections using cell-free DNA profiling; Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA; and rapid identification of antimicrobial resistance and other microbial phenotypes using highly-multiplexed fluorescence in situ hybridization); stock options as a member of the scientific advisory board for GEn1E Lifesciences and Nomic Bio; and equity as co-founder of Kanvas Biosciences.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu